DSM Biologics and Crucell N.V. Announce PER.C6(R) Technology Licensing Agreement with Recepta Biopharma S.A.

Sittard/Leiden, The Netherlands, November 2, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6® technology research licensing agreement with Brazilian-based Recepta Biopharma S.A. This agreement allows Recepta Biopharma to use the PER.C6® technology to develop four antibodies it has licensed-in from the Ludwig Institute for Cancer Research. Financial details were not disclosed.

MORE ON THIS TOPIC